Showing 51 - 60 of 148,414
Physicians’ generic pharmaceutical adoption involves not only patients’ and insurance payers’ cost, but also their own interests. This study examines this double agency problem for physicians by using Taiwanese data because two of its institutional features: First, patients and physicians...
Persistent link: https://www.econbiz.de/10014129240
of brand name pharmaceuticals, while the results regarding generics are less clear. In the empirical part of the paper …, the introduction of the substitution reform in the Swedish pharmaceuticals market in October 2002 is used as a natural … reform has lowered the price of both brand name and generic pharmaceuticals …
Persistent link: https://www.econbiz.de/10014260998
This paper examines generic entry into the Japanese pharmaceutical market. Relatively little is known about generic entry in regulated markets. Using micro data between 2003 and 2005, I find that generic entry is sensitive to the prescription pattern driven by the price regulation and healthcare...
Persistent link: https://www.econbiz.de/10014210344
Motivated by the slow diffusion of generic drugs and the increase in prices of brand-name drugs after generic entry, I incorporate consumer learning and consumer heterogeneity into an empirical dynamic oligopoly model. In the model, firms choose prices to maximize their expected total discounted...
Persistent link: https://www.econbiz.de/10012755155
Healthcare payers try to reduce costs by promoting the use of cheaper generic drugs. We show strong interrelations in drug prescriptions between the inpatient and outpatient sectors by using a large administrative dataset from Austria. Patients with prior hospital visits have a significantly...
Persistent link: https://www.econbiz.de/10011570769
(chemical substances) in Norway, we find strong evidence for the importance of both doctor and patient characteristics for the …
Persistent link: https://www.econbiz.de/10003751872
experiment from Norway, which in 2003 introduced a reference price (RP) system called index pricing for a sub-sample of off …-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …
Persistent link: https://www.econbiz.de/10010264178
We study effects of direct-to-consumer advertising (DTCA) in the prescription drug market. There are two pharmaceutical firms providing horizontally differentiated (branded) drugs. Patients differ in their susceptibility to the drugs. If DTCA is allowed, this can be employed to induce...
Persistent link: https://www.econbiz.de/10013318409
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10012802183
We investigate the effect of variations in the price of opium in Afghanistan on per capita dispensation of prescription opioids in the US. Quarterly county-level data for 2003-2016 indicate that reductions in opium prices significantly increase the quantity of opioids prescribed. The increase...
Persistent link: https://www.econbiz.de/10012843718